Safety and Pharmacokinetic Study of Intranasal 2-DG in Healthy Volunteers

Inclusion Criteria: * Healthy male or female volunteers, age ≥ 18 years old at screening * Females must be post-menopausal (\> 1 year since last menstruation) * Able to comprehend and to give informed consent * Able to cooperate with the investigator, to comply with the requirements of the study, and to complete the full sequence of protocol-related procedures * Undergone full immunisation against SARS-CoV2 or status post infection with SARS-CoV2 (both as defined by the Austrian Ministry of Health) Exclusion Criteria: * Frequent epistaxis (equal to or greater than 1/month) * Hypo- or anosmia * Symptoms of rhinitis, allergy or common cold disease at screening and at study initiation * Medical history of diabetes mellitus of any type * Clinically relevant abnormal findings at screening * Preceding nasal surgery or sinus surgery * Medical history of allergic rhinitis or chronic condition of the upper or lower respiratory tract with active symptoms within 30 days prior to screening * SARS-CoV-2 infection positive by PCR test at screening * Vulnerable subjects as defined by GCP * Subjects in a dependency relationship towards the investigators, e.g. as employees * Substance abuse, mental illness, or any reason that makes it unlikely in the judgment of the investigator for the subject to be able to comply fully with study procedures * Use of medication (including prophylactic treatments) during 2 weeks before the start of the study, which in the judgment of the investigator may adversely affect the subject's welfare or the integrity of the study's results * Concurrent treatment with other experimental product or participation in another clinical trial with any investigational product within 30 days or 5 elimination half-lives (whichever is longer) prior to treatment start * Scheduled vaccination appointments during the study period